Pharmacosmos vs. Dr. Reddy’s: Trilaciclib Patent Consolidation in ANDA Litigation
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Pharmacosmos A/S et al. v. Dr. Reddy’s Laboratories, Ltd. et al. |
| Numéro de dossier | 2:25-cv-03967 (D.N.J.) |
| Tribunal | Tribunal fédéral de première instance pour le district du New Jersey |
| Durée | May 7, 2025 – January 6, 2026 244 days |
| Résultat | Consolidated (Pretrial) |
| Brevets en cause | |
| Produits incriminés | Generic COSELA® (trilaciclib) for injection, intravenous drug product |
Aperçu du dossier
Les parties
⚖️ Demandeur
Holder and licensee of an extensive patent portfolio covering trilaciclib, a CDK4/6 inhibitor approved by the FDA for decreasing chemotherapy-induced myelosuppression.
🛡️ Défendeur
Global generic pharmaceutical manufacturer with a long history of ANDA filings challenging branded drug exclusivity across therapeutic categories.
Brevets en cause
This landmark case involved 13 U.S. patents spanning formulation, synthesis, method-of-use, and composition claims, reflecting a deliberate lifecycle management strategy common in complex small-molecule pharmaceutical litigation.
- • US8598186B2 / US8598197B2 — Core chemical entity and synthesis patents
- • US9487530B2 / US9957276B2 — Compound and formulation claims
- • US10085992B2 / US10189849B2 / US10189850B2 — Extended method and composition claims
- • US10927120B2 / US10966984B2 / US11040042B2 — Later-generation formulation and use patents
- • US11529352B2 / US11717523B2 / US12168666B2 — Most recent continuations covering expanded therapeutic indications and dosing regimens
Vous développez un produit pharmaceutique similaire ?
Check if your pipeline drug might infringe these or related patents before clinical trials.
Le verdict et l'analyse juridique
Résultat
The case closed through a court-approved stipulation of consolidation, not a merits verdict, damages award, or contested ruling. All three ANDA actions — against Teva, Hetero, and Dr. Reddy’s — were consolidated for pretrial purposes into the lead docket, Civil Action No. 2:25-cv-03218. No damages figure, injunctive relief order, or findings of infringement or validity were disclosed in the available record for this docket entry. The specific basis of termination for Case No. 2:25-cv-03967 as a standalone docket reflects administrative closure upon consolidation, not substantive resolution of infringement claims.
Principales questions juridiques
The infringement action was triggered by Dr. Reddy’s ANDA Paragraph IV certification — a statutory assertion that Pharmacosmos’s patents are either invalid, unenforceable, or will not be infringed by the generic product. Pharmacosmos’s decision to assert all 13 patents simultaneously signals a broad, portfolio-wide enforcement strategy designed to maximize the 30-month regulatory stay and increase settlement leverage across multiple generic challengers simultaneously.
The consolidation stipulation itself represents a strategic and procedural development of note. By agreeing to unified pretrial proceedings, both sides acknowledged efficiency benefits while preserving flexibility for trial strategy. Plaintiffs benefit from streamlined discovery and coordinated claim construction proceedings; defendants retain the option to pursue individualized infringement or invalidity arguments at trial.
Analyse de la liberté d'exploitation (FTO)
Ce cas met en évidence les risques critiques liés à la propriété intellectuelle dans le développement de produits pharmaceutiques. Choisissez la prochaine étape :
📋 Understand This Litigation’s Impact
Learn about the specific risks and implications from this multi-defendant ANDA case.
- View all 13 asserted patents and their claim families
- See which companies are most active in trilaciclib IP
- Understand legal arguments in similar ANDA cases
🔍 Check My Pipeline Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical technology.
- Input your drug candidate description or features
- AI identifies potentially blocking patents (composition, method of use, formulation)
- Get actionable risk assessment report for early development
Zone à haut risque
CDK4/6 inhibitors for myeloprotection
13 brevets revendiqués
Covering multiple claim types
AI-Powered FTO
Available for rapid risk screening
✅ Points clés à retenir
Multi-defendant ANDA consolidation under Rule 42 is gaining traction in D.N.J. and can reshape litigation economics for both sides.
Rechercher la jurisprudence connexe →A 13-patent assertion portfolio covering composition through method-of-use creates maximum regulatory and litigation leverage under Hatch-Waxman.
Explorer les précédents →Continuation claim families filed post-NDA approval remain fully assertable against ANDA filers, even for patents issuing after generic filing.
Analyze patent issuance trends →Administrative case closure upon consolidation does not represent merits resolution — monitor the lead docket (No. 2:25-cv-03218) for substantive developments.
Track related dockets →Foire aux questions
Pharmacosmos asserted 13 U.S. patents, including US8598186B2, US9487530B2, US10927120B2, US11717523B2, and US12168666B2, covering composition, synthesis, formulation, and method-of-use claims related to trilaciclib (COSELA®).
The case was administratively closed following court-approved consolidation with related ANDA litigations against Teva and Hetero Labs into lead docket No. 2:25-cv-03218. Pretrial proceedings continue under the consolidated case.
The consolidation of three simultaneous ANDA challenges creates a unified pretrial forum that may shape claim construction rulings and invalidity arguments applicable to all three generic challengers, with significant implications for COSELA® market exclusivity.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- PACER — Accès public aux dossiers judiciaires électroniques
- Centre des brevets de l'USPTO
- Cornell Legal Information Institute — 21 U.S.C. § 355 (Hatch-Waxman Act)
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 42
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.